1998 The CenterWatch Monthly

The CenterWatch Monthly Archive

Single archived issues of The CenterWatch Monthly are available for $79 each.

To order the PDF version of any issue, click on the “Add to Cart” button on this page. To order the print version, click on the desired issue and select “Print” from the format menu.

1998 (Volume 5)

    January

    The Top Ten Stories of 1997

    In 1997, CROs moved to develop alliances with sites, SMOs secured funding, PPMs discovered clinical research, and the SEC began cracking down on "bad apples," CenterWatch looks back on a busy year and reviews the top headlines

    Looking Ahead: Predictions for 1998

    CenterWatch publisher Ken Getz presents his observations and forecasts for the clinical trials industry in 1998.

    Data is presented describing shifts in pharmaceutical company clinical research spending, and comparing physician and patient resources in independent investigative sites, SMOs, HMOs, integrated healthcare systems and PPMs.

    Eye On: Migraine

    CenterWatch editorial staff review new treatments being researched for migraine and identify 20 investigational drugs in clinical development for this illness.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    February

    Sponsors Send Mixed Message to CROs

    CenterWatch in-depth survey of 15 sponsors finds that concerns over quality and cost may slow -- but not halt -- growth in outsourcing of clinical development services.Sponsors are developing diverse approaches for more effective, strategic management of CRO services.

    Bristol-Myers Squibb: A Reform Model for Partnering with CROs?

    Bristol-Myers Squibb spent a year remaking how it works with CROs; new master contracts include performance standards

    Eye On: Melanoma

    CenterWatch editorial staff review new treatments in research for melanoma and identify 37 investigational drugs in clinical development for this illness.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    March

    Practice-Based Sites Prosper

    Experienced community physicians report rising revenues and profits. They also cite improved relationships with sponsors and CROs.

    On The Path To Proactive Patient Recruitment

    CROs are taking the lead in developing centralized programs for accelerating patient recruitment. Amgen is model among sponsors for dedicated patient recruitment department.

    Eye On: Hypertension

    CenterWatch editorial staff review new treatments in research for hypertension and identify 28 investigational drugs in clinical development for this illness.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    April

    Dedicated Sites Buoyed by Hot Market

    CenterWatch surveys 36 full-time research sites and shows that most are experiencing a significant increase in demand for their services. In spite of stagnating study budgets, the majority of full-time sites report higher profits due to higher volume of studies.

    New Buyers for Sites Emerge

    Start-up SMOs are heating up the site-acquisition market.CenterWatch looks at seven active SMO buyers and their acquisition strategies.

    Eye On: Diabetes

    CenterWatch combs the R&D pipeline and finds 31 therapies for diabetes in clinical testing.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    May

    Rethinking Market Size

    CenterWatch research looks at overall spending for study conduct services. The results show that an estimated $2.66 billion was spent for these services, nearly twice the level of spending in 1992. 1998 Market share by investigative site type is presented.

    Pharmacogenomics: Reshaping the Future of Drug Development

    CenterWatch editorial explores how genomics research will dramatically expand the number of investigational drugs in development. Charts pharmaceutical companies' investment in genomic companies are presented.

    Eye On: Diabetes Complications

    CenterWatch editorial staff review new treatments in research for diabetes-related complications and identify 53 compounds in preclinical and clinical development.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    June

    European Sites Rate Sponsors

    CenterWatch presents the results of its first survey of European sites.Sixty percent of the 300 European sites surveyed rate Eli Lilly best in overall performance. Respondents to the survey said that top-rated sponsors use of local offices and on-staff CRAs are key in maintaining successful relationships with European investigators.

    SMOs Chalking Up Mixed Results

    CenterWatch editors show that most activity in the SMO market is being driven by only a handful of companies. Many SMOs are not performing well financially.Clinical Studies, Affiliated Research Centers, and Hill Top Research are considered the top three SMOs while MDS Harris, Protocare, and Clinical reSearchNet are making news as up-and-comers.

    Eye On: Breast Cancer

    CenterWatch editorial staff review new treatments in research for breast cancer and identify 39 therapies in clinical development.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    July

    U.S. CROs Rate Well Abroad

    U.S. CROs in Europe receive largely positive ratings by almost 300 European investigative sites. Top rankings go to Quintiles and ClinTrials.

    Quintiles Developing Contract Study-Coordinator Services

    Quintiles announces plan to hire study coordinators for temporary placement with sites as part of the company's "Total Acceleration" program.

    Eye On: Neuroleptics

    CenterWatch editorial staff review new neuroleptics in research for the treatment of schizophrenia and other psychotic disorders and identify 14 therapies in clinical development.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    August

    Feds Put IRBs Under Review

    CenterWatch looks at the state of the IRB approval process-in both academic and commercial centers. This story addresses conclusions by the Office of the Inspector General of Health and Human Services' in a report entitled: "IRBs: A Time for Reform". Reform suggestions include redefining federal IRB requirements to allow for more flexibility and accountability for results.

    Don't Call This Alliance an SMO

    Alliance for Multispecialty Research (AMR) is a network of 19 members with 24 sites who see their group of independently owned sites as the SMO path not taken. This CenterWatch feature article presents a look at alternative study conduct models now emerging.

    Eye On: Obesity

    CenterWatch editorial staff review new treatments research in obesity treatments and identify six compounds in clinical development and 21 in preclinical development.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    September

    The Evolving CRO Market

    CROs' revenue growth in first six months of 1998 tops 30%. However, a number of mid-sized CROs are struggling with profitability. A CenterWatch analysis of 16 publicly traded CROs found that their revenues during the first six months of 1998 totaled $1.49 billion.

    Don't Let Your Study Coordinator Get Away

    Sites are using various approaches to retain their study coordinators. Examples include flexible work schedules and profit-sharing. This article presents benchmark information on coordinator salaries and experience.

    Eye On: Irritable Bowel Syndrome

    CenterWatch editorial identifies six investigational therapies for irritable bowel syndrome.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    October

    A Warming Relationship With MCO

    A large percentage of patients who receive their primary care from a managed care organization are now participating in clinical trials though indirectly. A CenterWatch survey reveals that sponsors and CROs want to work more closely with staff-model MCOs over the next two years. Sponsor interest in MCOs is primarily for access to patients and rich data sources. A distant secondary interest is access to formulary.

    Sponsors Evaluate Building In-House CROs

    Sponsors report that they are becoming more selective in their use of CROsMany sponsors report that they are increasing their use of temporary agencies and independent contractors. About 42% of sponsors surveyed for this story said that they believe CRO costs are up to 25% more expensive than those of in-house resources.

    Eye On: AIDS/HIV

    CenterWatch editorial staff confirms 50 therapies in the pipeline for the treatment of AIDS, HIV and related illnesses.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    November

    The Difficulties of Site Integration

    The pace of investigative sites acquisitions has accelerated given SMOs that now have access to substantial capital. Now, however, SMOs are reporting significant difficulties integrating investigative sites post acquisition. Integration success stories highlight the importance of up-front planning and communication to set expectations.

    Bonuses to the Rescue

    Sponsor and CRO companies have been experimenting with a variety of changes to study conduct contracts in order to motivate investigative sites to perform more efficiently and effectively. Investigative sites discuss their perspective on various bonus programs. They describe patient recruitment bonuses as the most important incentive area for sponsors and CROs to modify.

    Eye On: Prostate Cancer

    CenterWatch editorial reports on investigational treatments for prostate cancer. Forty-eight preclinical and clinical treatments are identified.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00
    December

    Losing Ground in the Battle Against Development Delays

    According to a recent 1998 CenterWatch survey, investigative sites believe that the largest cause of development delays is the contracting and budgeting process.CRO involvement in clinical projects is creating greater inefficiencies according to the survey of 150 investigative sites.

    Private CROs Thrive Out of the Public Eye

    Private CROs are reporting strong growth, free from public market volatility.Many private CROs are achieving some vertical integration and global expansion through affiliations and alliances.

    Eye On: Depression

    CenterWatch research focuses on 24 new treatments for depression.

    • Month in Review
    • TrialWatch
    (read more...)
    Price: $79.00